Novo Nordisk is committed to doing everything we can to improve the treatment of diseases.  This includes providing as much information as we can to healthcare professionals, healthcare organisations and patients about the proper use of the medicines and delivery systems we manufacture.

Collaborations with healthcare professionals and healthcare organisations help us to drive innovation and develop new medicines, enhance quality of health education and identify patient needs.

Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guideline, namely the ABPI Code of Practice.  We believe transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.

Novo Nordisk works alongside Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) to improve the development and delivery of life-enhancing and life-saving medicines for patients.

To ensure that patients have confidence in these relationships, the pharmaceutical industry is taking the lead on disclosing details of payments and other benefits in kind made by Novo Nordisk to HCPs and HCOs.

In-line with current ABPI requirements, Novo Nordisk submits information regarding transfers of the value made to healthcare organisations and healthcare professionals to the ABPI central disclosure platform.  For further information, please visit  www.disclosureuk.org.uk.

In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Novo Nordisk UK are providing details of the Patient Organisations it partners with, including the nature and financial element of each instance of support.

2019 support provided to UK Patient Organisations

Patient Organisation  Description of activity or project support  Net value of support (£)

Association of Children's Diabetes

Sponsorship of the 13th ACDC Annual Conference (1st Feb. 2019, stand space)

£3,000.00

Child Growth Foundation

Health professional awareness/education project

£4,580.83

Diabetes UK

Sponsorship of the 7th National Diabetes in Pregnancy Annual Conference (exhibition stand)

£6,000.00

Diabetes UK

Support of the Diabetes UK Clinical Champions Programme 2018

£75,000.00

Diabetes UK

Support towards the 'Tomorrows Leaders Training Programme 2018', which provides Diabetes Specialist Nurses and Dieticians with the skills and confidence to become strong local leaders to ensure that the best diabetes care is delivered in their area

£20,539.00

Diabetes UK

Sponsorship of the West Midlands Footcare Conference (13 Nov. 2018, stand space)

£83.33

Diabetes UK

Sponsorship of the Diabetes UK Professional Conference (6-8 Mar. 2019,  Silver Corporate Sponsorship, 2x Symposium, Workshop, Exhibition Stand Space)

£78,782.00

Diabetes UK

Support towards the Pharmacy Leaders Programme 2019,  which provides Pharmacists with the skills and confidence to become strong local leaders to ensure that the best diabetes care is delivered in their area

£46,587.00

Diabetes UK

Support towards the 'Tomorrows Leaders Training Programme 2019', which provides Diabetes Specialist Nurses, Dieticians and Podiatrists with the skills and confidence to become strong local leaders to ensure that the best diabetes care is delivered in their area

£34,172.00

Diabetes UK

Support of the Diabetes UK Clinical Champions Programme

£181,330.00

Diabetes UK

Sponsorship of the 8th National Diabetes in Pregnancy Annual Conference (21 Nov. 2019, exhibition stand)

£6,000.00

Diabetes UK

To support the update of the orange booklet for people newly diagnosed with Type 2 diabetes

£8,500.00

Diabetes UK

Support of ChangeLabs 2019 (series of workshops for healthcare professionals working in diabetes to improve diabetes care)

£30,000.00

Diabetes UK

Sponsorship of the Diabetes UK South West Professional Conference (9 Oct. 2019, exhibitor stand)

£450.00

Diabetes UK

Sponsorship of the Walsall Footcare Conference (12 Nov. 2019)

£100.00

Diabetes UK

Sponsorship of YDEF ABCD of E (21-22 Nov. 2019)

£5,000.00

Diabetes UK

Donation

Provision of Glucagon® Hypokits® by Novo Nordisk to support the Type 1 events organised and run by Diabetes UK during 2019

Haemophilia Scotland

To support the review of Extended Half Life Product Animation Education Material

£150.00

Haemophilia Scotland

Support of an event for 12 young people with bleeding disorders

£1,621.00

Heart UK

12 months corporate membership

£24,000.00

The Haemophilia Society

Donation towards a family day activity

£5,000.00

The Patients Association

12 months corporate membership

£12,000.00

The Patients Association

Sponsorship of a project to empower patients and provide information and support when switched to biosimilar medications (May 2019 - Oct. 2019)

£12,500.00

Turner Syndrome Support Society (TSS)

Sponsorship of Annual conference 2019 and membership database update

£4,166.67

 

2018 support provided to UK Patient Organisations

2017 support provided to UK Patient Organisations

2016 support provided to UK Patient Organisations

 

Novo Nordisk is committed to working with the NHS to improve patient healthcare and welcomes the recent move from the Department of Health and the Association of British Pharmaceutical Industry (ABPI) which formalises how the NHS and the pharmaceutical industry work together in a more transparent business-to-business manner for the benefit of patients under the Joint Working framework.

In the Joint Working Toolkit for Industry and the NHS, the Department of Health and Social Care defines Joint Working as “Situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centered projects and share a commitment to successful delivery."

Please find below details of Novo Nordisk's Joint Working Projects.

Projects commenced 2016 onwards

Novo Nordisk is committed to transparency in our clinical research and continues to comply with the laws and regulations related to the registration and disclosure of Novo Nordisk sponsored clinical study information.

For further information about clinical trials sponsored by Novo Nordisk click here.

In line with Gender Pay Gap Reporting (GPGR) regulations, all UK companies with more than 250 employees are required to publish their GPGR statistics using data as of 5th April 2020. The metrics cover the gap in pay, the gap in bonus payments, the proportion of men/women at different pay quartiles, and proportion of men/women receiving bonus pay-outs over the previous 12 months period (6 April 2019 to 5 April 2020).

At Novo Nordisk Limited, we are committed to treating pay equality, and diversity and inclusion, with the highest priority. We have a number of activities focused on ensuring that male and female employees are paid equally for work of the same value, and we do not tolerate discrimination on gender or any other protected grounds.

Download our 2020 report